Pine Labs faces pressure as Emkay assigns ‘reduce’ rating; target set below IPO price - niveshvani.in

Pine Labs faces pressure as Emkay assigns ‘reduce’ rating; target set below IPO price

Shares of fintech company Pine Labs came under selling pressure on Thursday, November 20, after domestic brokerage firm Emkay Global initiated coverage on the counter with a ‘reduce’ recommendation and a target price significantly below the IPO issue price.

Pine Labs shares declined nearly 2.8% intraday to ₹235.30, compared to the previous close of ₹242.10. Emkay’s target price of ₹210 implies a potential downside of around 13% from the latest close and takes the stock below the IPO issue price of ₹221.

The scrip continues to trade 17% lower than its listing-day high of ₹283.70, which remains the peak level for the counter since market debut.


Why is Emkay cautious on Pine Labs?

The brokerage highlighted three key reasons behind its bearish stance:

1. Rising competitive intensity

Pine Labs maintains a strong presence in the enterprise PoS (point-of-sale) business and is a leader in EMI aggregation. However, competition is rising as new players aggressively enter the segment. At the same time, India’s payment ecosystem is shifting rapidly from physical PoS devices to QR-based solutions, posing a structural headwind.

While Pine Labs has been pushing low-end Mosambee smart devices to target small merchants, Emkay believes its distribution reach remains weaker than rivals, limiting growth opportunities.

The brokerage estimates a modest revenue CAGR of 18.8% for FY25–FY28 for its core Digital Infrastructure and Transaction Processing (DITP) business due to competitive and structural challenges.

2. Limited scalability in the gift-card business

Pine Labs’ gift-card segment in India is profitable but growing at a tepid pace. Instead, international operations are driving expansion, with a 192% CAGR between FY22 and 9MFY25 — but margins have been highly volatile, ranging from 0.5% to 56.3% during this period.

With domestic growth muted and overseas margins inconsistent, Emkay sees limited long-term growth visibility from this business.

3. Premium valuation despite risks

At prevailing prices, Pine Labs trades at:

  • 28.1× FY28E EV/EBITDA

  • 56.4× FY28E P/E

The brokerage notes that given its maturing POS business, stiff competition, and declining market share, the stock’s valuation looks expensive, making the risk–reward proposition unfavourable.

As a result, Emkay Global initiated coverage with a target price of ₹210, valuing the company at 24.2× FY28E EV/EBITDA.


IPO performance so far

Pine Labs debuted strongly on the stock exchange last Friday, closing with a 14% premium over its issue price of ₹221. The stock surged nearly 29% intraday on listing day.
The response to the IPO was modest, with an overall subscription of 2.46×, driven primarily by QIB participation.

Proceeds from the fresh issue are earmarked for:

  • Debt repayment

  • Investment in IT assets and cloud infrastructure

  • Technology development initiatives

  • Procurement of digital checkout points


Outlook

While Pine Labs continues to enjoy strong brand equity in the merchant payment ecosystem, analysts believe the near-term outlook may remain subdued due to:

  • Intensifying industry competition

  • Shift of merchants toward low-cost QR solutions

  • Slower scalability in domestic gift-card operations

  • Elevated valuation multiples

Market participants are expected to closely monitor the company’s merchant acquisition growth, revenue traction and margin profile in upcoming quarters to assess whether earnings progress can justify current valuations.

Abhishek Sinha

Abhishek Sinha is a young and dynamic journalist with 2 years of experience in business news reporting and analysis. Over this period, he has developed strong expertise in covering stock markets, corporate developments, IPOs, economic policies, and sector-specific trends.

Related Posts

Upcoming IPOs Next Week: Wakefit, ICICI Prudential AMC Among 13 New Issues Set to Open

The primary market is gearing up for one of its most active weeks, with 13 fresh IPOs lined up across both the mainboard and SME segments. Investors will see several…

Invicta Diagnostic IPO opens; issue subscribed 9% on Day 1 — GMP, price band and key highlights

The ₹28 crore IPO of Invicta Diagnostics opened for subscription on Monday, December 1, and will remain open until Wednesday, December 3. The diagnostic services provider aims to deploy the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Standard Chartered Refreshes Priority Banking Proposition in India

Standard Chartered Refreshes Priority Banking Proposition in India

आईसीआईसीआई लोम्बार्ड की प्रीमियम ग्रोथ Q3 में 13% बढ़कर करीब ₹70,000 करोड़

आईसीआईसीआई लोम्बार्ड की प्रीमियम ग्रोथ Q3 में 13% बढ़कर करीब ₹70,000 करोड़

एयू स्मॉल फाइनेंस बैंक ने संक्रांति पर पेश किए देशभर में आकर्षक उत्सव ऑफ़र्स

एयू स्मॉल फाइनेंस बैंक ने संक्रांति पर पेश किए देशभर में आकर्षक उत्सव ऑफ़र्स

जियोब्लैकरॉक इन्वेस्टमेंट एडवाइजर्स ने लॉन्च की आधिकारिक वेबसाइट, अर्ली एक्सेस कैंपेन की शुरुआत

जियोब्लैकरॉक इन्वेस्टमेंट एडवाइजर्स ने लॉन्च की आधिकारिक वेबसाइट, अर्ली एक्सेस कैंपेन की शुरुआत

एयू स्मॉल फाइनेंस बैंक ने संक्रांति पर देशभर में पेश किए खास फेस्टिव ऑफ़र्स

एयू स्मॉल फाइनेंस बैंक ने संक्रांति पर देशभर में पेश किए खास फेस्टिव ऑफ़र्स

Sandeep Walunj Appointed Chief Growth Officer at Equirus Group

Sandeep Walunj Appointed Chief Growth Officer at Equirus Group